TXMD Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
1.3M
+44.9%
869.0K
+20.0%
724.0K
-18.9%
893.0K
+13.9%
784.0K
Cost of Revenue
0
0
0
0
0
Gross Profit
1.3M
+44.9%
869.0K
+20.0%
724.0K
-18.9%
893.0K
+13.9%
784.0K
Operating Expenses
1.7M
+3.1%
1.7M
+16.4%
1.4M
-40.8%
2.4M
+48.5%
1.6M
R&D
0
0
0
0
0
SG&A
1.6M
+4.1%
1.6M
+16.6%
1.4M
-41.0%
2.3M
+51.0%
1.5M
Operating Income
-479000
+41.3%
-816000
-12.9%
-723000
+53.4%
-1552000
-80.0%
-862000
EBITDA
-382000
+47.0%
-721000
-14.6%
-629000
+60.1%
-1575000
-105.6%
-766000
Net Income
491.0K
+216.8%
155.0K
+63.2%
95.0K
+115.3%
-619000
-507.2%
152.0K
EPS (Basic)
$0.04
+300.0%
$0.01
+0.0%
$0.01
+120.0%
$-0.05
-600.0%
$0.01
EPS (Diluted)
$0.04
+300.0%
$0.01
+0.0%
$0.01
+120.0%
$-0.05
-600.0%
$0.01
Shares (Diluted)
11.6M
+0.0%
11.6M
+0.0%
11.6M
+0.6%
11.6M
+0.0%
11.6M
TherapeuticsMD (TXMD) — Financials